The medication ocrelizumab is the first treatment to show it can slow disability progression for people with primary progressive MS.
Ocrelizumab can slow progression of MS. This is according to the newly published results of its phase 3 trials.
It is the first treatment that can slow the advancement of primary progressive MS. It can also treat relapsing MS.
The full results of three final stage clinical trials were published in the New England Journal of Medicine today.
Treating primary progressive MS
In a phase 3 trial, ocrelizumab reduced the MS progression by 25% in people with primary progressive MS. This was compared with a placebo over the course of two years.
Scientists focused on symptoms defined in the Expanded Disability Status Scale. These include problems with walking, thinking and swallowing.
The team also found that treatment with ocrelizumab decreased the total volume of brain lesions seen on MRI, whereas lesion volume increased in those treated with placebo.
|Read Full Article: Publication of ocrelizumab trials: hope for progressive MS | Multiple Sclerosis Society UK|